Fetal Chromosomal Aneuploidy (T21, T18, T13) Test Kit (reversible termination sequencing)

NIPT is a prenatal screening method that uses high-throughput gene sequencing and molecular genetic techniques to detect fetal cell-free DNA fragments in maternal peripheral blood, assessing the risk of common fetal chromosomal aneuploidies (T21, T18, T13). The test extracts free DNA from maternal blood containing fetal genetic information and analyzes it through high-throughput sequencing to detect abnormalities in fetal chromosome number and structure. Compared to traditional maternal serum screening, NIPT offers advantages of high detection rate and low false positive rate, while avoiding the risks associated with invasive methods such as amniocentesis.

A comprehensive solution for prenatal testing including reagent kits and equipment for DNA sequencing and bioinformatic analysis. Sensitivity greater than 99% for detection of trisomies 21, 18, and 13, with capability to identify up to 100 genetic conditions and produce results within 14 hours.

A non-invasive prenatal test that analyzes fetal DNA from maternal blood using Next Generation Sequencing (NGS) technology. The test can be performed as early as 10 weeks of pregnancy with detection rates exceeding 99% accuracy. It is the first in Korea to analyze chromosomes 9, 16, and 22, as well as microdeletions, and eliminates the miscarriage risk associated with invasive procedures such as amniocentesis or chorionic villus sampling.

A noninvasive liquid biopsy service based on next-generation sequencing (NGS) technology that analyzes fetal DNA from maternal blood starting from week 10 of pregnancy in singletons and week 12 in twins. The service provides fetal sex identification and comprehensive chromosomal abnormality screening.

Next-generation non-invasive prenatal testing kit for screening common genetic conditions in singleton, twin, and IVF pregnancies. Utilizes proprietary sequencing technology with automated workflow capabilities for high-throughput prenatal screening.

PGT-A is an advanced genetic test used during in vitro fertilization (IVF) to screen for chromosomal abnormalities in embryos before implantation. The technology analyzes embryonic DNA using high-throughput sequencing (NGS) to help physicians select chromosomally normal embryos for implantation, improving IVF success rates and reducing miscarriage risk. PGT-A is primarily applied in assisted reproduction, particularly for couples with specific chromosomal abnormality risks, such as advanced maternal age, recurrent miscarriage history, or multiple IVF failures.

A prenatal diagnostic test for the detection of chromosomal number abnormalities in the fetus.

Diagnostic test kit for identification of genetic mutations and inherited disorders through nucleic acid sequencing. Supports clinical genetic testing and carrier screening applications.

Advanced non-invasive prenatal testing kit offering expanded genetic condition screening with high-content analysis capabilities. Integrates with laboratory workflow systems for multi-discipline testing on single sequencing runs.

A diagnostic kit for detecting chromosomal aneuploidy in embryos prior to implantation. The kit comes in 50 samples per box with a 6-month validity period and is identified by catalogue number J000001. It is used in clinical reproductive genetics for embryo screening.

Next-generation sequencing-based detection kit screening over 165 preventable genetic and metabolic diseases in newborns. Uses proprietary All-in-One PCR amplicon capture technology combined with NGS for early diagnosis and intervention.

Next generation sequencing panel for non-invasive prenatal testing (NIPT) and newborn screening (NBS). Provides precision genetic profiling for maternal and pediatric healthcare applications.